Indication

Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

Medicine details

Medicine name:
buprenorphine implant (Sixmo)
SMC ID:
SMC2372
Pharmaceutical company
Accord Healthcare
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
02 August 2021